The company has received 1 (ONE) observation on Form 483 with respect to ANDA filed for the product to be manufactured at the said Facility.
This Bioforum will provide the latest insights on delivering increased speed, greater flexibility and enhanced quality while reducing the cost, and risks of navigating the evolving biopharma landscape
JB Pharma is the fastest growing pharmaceutical company in FY 2021-22 and Q1 of FY 2022-23.
The initiative aims to reach out to more than 20 million people across the country and a number of social media influencers have also pledged to extend their whole-hearted support for the noble cause
The cash consideration for the above acquisition will be Euro 26 million.
Today, India stands at 1.7 nurses per 1,000 population, as opposed to the World Health Organization norm of 3 nurses per 1000.
The pandemic has taught us that health is not the exclusive responsibility of only the Union Health Ministry but jointly addressed by various Ministries at the centre and through state governments
The citizens of Oman will soon have a coordination center that will provide end to end services for healthcare facilities of Jaslok.
Celanese to conduct research, prototype development and characterization of a refillable contraceptive technology with award from the Bill & Melinda Gates Foundation
Fund VI will focus on investments in industrials and healthcare businesses with proven technologies and solutions positioned to deliver high performance and value-add to their customers
This rapid analytical technique provides additional information about the polymorph and solid-state properties of active pharmaceutical ingredients (APIs)
Bharat Swasth Mahotsav organises ‘Padma Doctors Congregation’ for Celebrating Healthcare Changemakers in India Since Independence
The summit to demonstrate revolutionary techniques and advanced medical procedures for treating CTO
This biopharmaceutical facility is one most significant private sector investment ever in the Middletown region
Genentech will be granted an exclusive license to develop and commercialize the degrader worldwide, and will be fully responsible for the development and commercialization costs.
The integrated services ensure that NextPoint can bring their molecule to the clinic in a timely manner.
The card-to-cloud device was launched into the U.S. and many other markets and is designed to work without an embedded communications module.
The estimated capex is to the tune of Rs. 140 crore to be funded through debt and internal accrual
The company has reported total income of Rs. 450.26 crores during the period ended June 30, 2022.
Subscribe To Our Newsletter & Stay Updated
_256_275.jpg)
